Cargando…

European randomized study of prostate cancer screening: first-year results of the Finnish trial

Approximately 20 000 men 55–67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial. In the first round, the participation rate in the screening arm was 69%....

Descripción completa

Detalles Bibliográficos
Autores principales: Määttänen, L, Auvinen, A, Stenman, U-H, Rannikko, S, Tammela, T, Aro, J, Juusela, H, Hakama, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362232/
https://www.ncbi.nlm.nih.gov/pubmed/10098761
http://dx.doi.org/10.1038/sj.bjc.6690194
_version_ 1782153406700322816
author Määttänen, L
Auvinen, A
Stenman, U-H
Rannikko, S
Tammela, T
Aro, J
Juusela, H
Hakama, M
author_facet Määttänen, L
Auvinen, A
Stenman, U-H
Rannikko, S
Tammela, T
Aro, J
Juusela, H
Hakama, M
author_sort Määttänen, L
collection PubMed
description Approximately 20 000 men 55–67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial. In the first round, the participation rate in the screening arm was 69%. Of the 5053 screened participants, 428 (8.5%) had a serum prostate-specific antigen (PSA) concentration of 4.0 ng/ml or higher, and diagnostic examinations were performed on 399 of them. A total of 106 cancers were detected among them corresponding to a positive predictive value of 27%, which is comparable with mammography screening for breast cancer. The prostate cancer detection rate based on a serum PSA concentration of 4.0 ng ml(−1) or higher was 2.1%. Approximately nine out of ten screen-detected prostate cancers were localized (85% clinical stage T1–T2) and well or moderately differentiated (42% World Health Organization (WHO) grade I and 50% grade II), which suggests a higher proportion of curable cancers compared with cases detected by other means. © 1999 Cancer Research Campaign
format Text
id pubmed-2362232
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23622322009-09-10 European randomized study of prostate cancer screening: first-year results of the Finnish trial Määttänen, L Auvinen, A Stenman, U-H Rannikko, S Tammela, T Aro, J Juusela, H Hakama, M Br J Cancer Regular Article Approximately 20 000 men 55–67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial. In the first round, the participation rate in the screening arm was 69%. Of the 5053 screened participants, 428 (8.5%) had a serum prostate-specific antigen (PSA) concentration of 4.0 ng/ml or higher, and diagnostic examinations were performed on 399 of them. A total of 106 cancers were detected among them corresponding to a positive predictive value of 27%, which is comparable with mammography screening for breast cancer. The prostate cancer detection rate based on a serum PSA concentration of 4.0 ng ml(−1) or higher was 2.1%. Approximately nine out of ten screen-detected prostate cancers were localized (85% clinical stage T1–T2) and well or moderately differentiated (42% World Health Organization (WHO) grade I and 50% grade II), which suggests a higher proportion of curable cancers compared with cases detected by other means. © 1999 Cancer Research Campaign Nature Publishing Group 1999-03 /pmc/articles/PMC2362232/ /pubmed/10098761 http://dx.doi.org/10.1038/sj.bjc.6690194 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Määttänen, L
Auvinen, A
Stenman, U-H
Rannikko, S
Tammela, T
Aro, J
Juusela, H
Hakama, M
European randomized study of prostate cancer screening: first-year results of the Finnish trial
title European randomized study of prostate cancer screening: first-year results of the Finnish trial
title_full European randomized study of prostate cancer screening: first-year results of the Finnish trial
title_fullStr European randomized study of prostate cancer screening: first-year results of the Finnish trial
title_full_unstemmed European randomized study of prostate cancer screening: first-year results of the Finnish trial
title_short European randomized study of prostate cancer screening: first-year results of the Finnish trial
title_sort european randomized study of prostate cancer screening: first-year results of the finnish trial
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362232/
https://www.ncbi.nlm.nih.gov/pubmed/10098761
http://dx.doi.org/10.1038/sj.bjc.6690194
work_keys_str_mv AT maattanenl europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT auvinena europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT stenmanuh europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT rannikkos europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT tammelat europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT aroj europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT juuselah europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial
AT hakamam europeanrandomizedstudyofprostatecancerscreeningfirstyearresultsofthefinnishtrial